58 results about "Muscle disorder" patented technology

A phosphorothioate-containing RNA molecule that includes the nucleotide sequence: 5'-NCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC-3' (SEQ ID NO: 1), where N is uracil or thymine, is provided. The RNA molecule can include one or more phosphorothioate bonds between nucleic acid residues in one or more pairs (e.g., between nucleic acid residues in each pair) of consecutive nucleic acid residues within SEQ ID NO: 1. The RNA molecule and compositions thereof find use in treating muscle disorders, such as muscular dystrophy, heart conditions, such as heart failure or myocardial infarction, and / or conditions associated with inflammation and / or fibrosis.

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

To provide an antisense oligonucleotide for preventing, delaying, and / or treating a human cis-element repeat instability-associated genetic disorder.SOLUTION: A medicament comprises, as an active ingredient, an oligonucleotide, wherein the oligonucleotide comprises 2'-O-methyl RNA nucleotide residues, has a backbone with at least one phosphate moiety being replaced by a phosphorothioate moiety, and comprises or consists of a repetitive nucleotide unit (XYG)m, wherein m is an integer from 4 to 12, each X is C or 5-methylcytosine, each Y is U or 5-methyluracil, and at least one X is 5-methylcytosine.SELECTED DRAWING: None

Provided herein are compounds of Formula (I): (I), or a pharmaceutically acceptable salt or composition thereof, which are useful in the treatment or management of diseases or disorders mediated by AAK1 activity, muscle diseases and disorders, and other conditions.

The portable controllable suspension vibrator for rehabilitation is installed on a rope of a suspension instrument and comprises a shell, a vibration motor and two vibration plates, the vibration motor is arranged in the shell, and the two vibration plates are symmetrically arranged at the two ends of the shell and extend in the length direction of the shell; the front end faces of the two vibration plates are each provided with a connecting piece, and the two connecting pieces are symmetrically arranged and detachably connected with the corresponding ropes. According to the utility model, the suspension apparatus of the rehabilitation training device is connected with the vibrating plate through the rope, the vibrating plate is vibrated through the vibrating motor, and the vibration is transmitted to a patient on the rehabilitation training device through the rope, so that the patient is subjected to vibration treatment, and the rehabilitation training device is used for assisting in treating neuromuscular diseases, relieving pain, activating muscle functions and the like. The device is externally connected to the rehabilitation training device and can be adjusted according to the requirements of a patient, the structure of an original rehabilitation training device does not need to be changed, installation is convenient, and cost is low.

The invention relates to constitutively active mutants of the transcription factor TFEB, which can mutate the lysine of one or both sites of positions 219 and 347; and / or also mutate the glutamic acid of one or both sites of positions 221 and 349, in order to eliminate the SUMOylation of the protein. By replacing these residues either from positions 219 and / or 221 and / or 347 and / or 349 by any other amino acid (such as arginine or alanine), it gives rise to a mutated TFEB, which more actively induces the expression of genes and protein synthesis of the lysosomal and autophagic pathway. Such as lysosomal storage disorders, neurodegenerative diseases, liver diseases, muscle diseases and metabolic diseases, and / or disorders or processes in the aging of the skin.

The invention belongs to the technical field of biology, and discloses an application of sodium crotonate in the aspect of regulating and controlling muscle development, and an application of sodium crotonate in serving as and / or preparing a medicine for regulating and controlling muscle development. The invention discloses the dual effects of sodium crotonate in skeletal muscle development regulation for the first time, and provides a new potential target and a chemical intervention approach for muscle regeneration and treatment of atrophic myopathy and metabolic muscle diseases. On the other hand, the sodium crotonate is a low-toxicity metabolite, can be used in conventional solution preparation and injection modes, and has application prospects.

The present disclosure generally relates to the treatment of subjects having muscle disorder or at risk of developing muscle disorder by administering a Folliculin Interacting Protein 1 (FNIP1) inhibitor and / or a Folliculin (FLCN) inhibitor to the subject.

The present invention discloses an oral muscle training system, comprising an oral muscle training space and an oral muscle training method on a computer built into the oral muscle training space, wherein a video module is installed on the top of the inner layer of the oral muscle training space, and a temperature and humidity control module is installed on the front and back lower parts of the inner layer of the oral muscle training space. The outer layer of the oral muscle training space is a solid wall, and the inner layer of the oral muscle training space is composed of 5 LED display screens. The video module, temperature and humidity control module, and LED display screen are all connected to the computer by wired or wireless communication; the oral muscle training method comprises the following steps: independently designing a training script or importing a standard training script; completing the training according to the training script; and evaluating the user to obtain an evaluation result. The present invention can provide a more interesting and effective training method for patients with oral muscle disorders, combining education with entertainment. The system of the present invention can automatically adjust the temperature and humidity during the training process to help users reduce sensitivity.

The apelin receptor modulator can improve the physical performance of a human patient, slow the progression of age-related weakness, and can reduce age-related muscle weakness. The present disclosure provides methods of treating muscle disorders using specific classes of apelin receptor modulators (e.g., agonists). The muscle condition may be an age-related muscle condition. Also provided is a method of maintaining and / or increasing muscle mass, muscle function, and / or muscle strength in an elderly subject by administering an apelin receptor modulator. In some embodiments, an apelin receptor modulator (e.g., an agonist) is BGE-105 or a pharmaceutically acceptable salt thereof.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

Described herein are polypeptides with an IGF2 amino acid sequence and an amino acid sequence from a heterologous polypeptide for treatment of soft-tissue and muscle diseases, disorders, and injuries. Mutations within the IGF2 amino acid sequence improved stability by reducing backbone cleavage. Synergistic combinations of an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid are also described. Methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and / or synergistic compositions are provided herein.

Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and / or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.

Disclosed herein are compositions that are useful for targeting a signaling pathway modulator to a muscle cell. In some instances, such compositions may be useful in treating a muscle disorder, such as muscular dystrophy.

The present invention relates to a phytochemical-containing albumin nanocomplex and a composition containing the same for improving muscle diseases. More specifically, the present invention relates to a phytochemical-containing albumin nanocomplex that has the effect of suppressing muscle loss caused by oxidative stress or inflammatory responses and promoting the differentiation of myoblasts into muscle cells. The phytochemical-containing albumin nanocomplex effectively delivers phytochemicals to immune cells that induce reactive oxygen species and inflammatory responses, thereby regulating the muscle loss signaling mechanism induced by reactive oxygen species and inflammatory responses, suppressing muscle cell atrophy, and promoting differentiation. This can improve muscle loss and prevent and treat muscle atrophy. Therefore, a composition containing the phytochemical-containing albumin nanocomplex of the present invention can be provided as a composition for improving muscle diseases.

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

The present invention includes novel aromatic molecules which can be used for treating pathological conditions in human and veterinary medicine, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system including the blood system.

A peptide of the present invention has muscle formation-promoting activity in myoblasts. The peptide of the present invention has the activities of inhibiting fat accumulation and promoting lipolysis in hepatocytes and adipocytes. The peptide of the present invention inhibits the expression of insulin resistance factors and increases the expression of insulin sensitivity factors in hepatocytes and adipocytes. Therefore, the peptide of the present invention can be used as an active substance for the treatment, prevention or amelioration of muscle diseases, obesity, fatty liver, and diabetes.

The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle diseases comprising an extract of *Ribesfasciculatum var. chinenseMaxim.* as an active ingredient. By confirming that the extract promotes the expression of muscle formation-related factors and inhibits the expression of muscle degradation-related factors in a cell model in which myotube differentiation inhibition or muscle atrophy is induced, the composition can be usefully utilized as a composition for the prevention, treatment, or improvement of muscle diseases.

Provided herein are compositions relating to genetically engineered muscle-specific promoters, including for example nucleic acids containing such promoters, vectors comprising such nucleic acids, and pharmaceutical compositions comprising such vectors. Methods ofproducing such nucleic acids and vectors, as well we methods of using such nucleic acids and vectors in, for example, gene therapy in treating muscle disorders, are also disclosed.

The invention discloses application of an internal ribosome entry site (IRES) element in circular RNA (Ribosome Entry Site). The IRES element can specifically drive target protein translation expression in the circular RNA in muscle cells. The invention also discloses a circular RNA (Ribosome Entry Site). The circular RNA comprises an internal ribosome Entry Site (IRES) element; the IRES element can specifically drive target protein translation expression in circular RNA in muscle cells. The invention also discloses a precursor RNA, a carrier and a pharmaceutical composition. The invention also discloses application of the circular RNA, the precursor RNA, the carrier or the pharmaceutical composition in preparation of drugs for preventing and / or treating muscle-related diseases. The IRES element can specifically drive target protein translation and high expression in circular RNA in muscle cells, different target proteins can be loaded, and a universal and efficient solution is provided for intramuscular injection of vaccines and treatment of various muscle diseases.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The present invention provides a polypeptide consisting of the sequence of SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and / or treatment of a muscle disease or disorder. The present invention also provides a nucleic acid sequence encoding the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the present invention may be administered in the form of a pharmaceutical composition, together with at least one pharmaceutically acceptable excipient, diluent, or carrier. The present invention also provides non-therapeutic methods for improving muscle function and / or increasing muscle mass in a subject.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

The present disclosure is generally directed to treating a subject having a muscle disorder or at risk of developing a muscle disorder by administering a follicin interacting protein 1 (FNIP1) inhibitor and / or a follicin (FLCN) inhibitor to the subject.

The present invention relates to the use of 2-chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).

Disclosed herein are 15-hydroxyprostaglandin dehydrogenase (PGDH) inhibitor compounds. Such compounds may be administered to subjects that may benefit from prostaglandin level modulation for the treatment of muscle disorders.

Disclosed herein are compositions that are useful for targeting a signaling pathway modulator to a muscle cell. In some instances, such compositions may be useful in treating a muscle disorder, such as muscular dystrophy.